Venture report: Rounds for psychedelic play Reunion, cancer company Delphia

Antidepressant developer Reunion and cancer company Delphia drew series A rounds this week, while a syndicate helped BridgeBio spin out its cancer programs and AbCellera teamed with a pair of investors to create asset-focused start-ups.

MPM BioImpact and Novo Holdings led a $103 million series A round for Reunion Neuroscience Inc. to advance a lead program to treat postpartum depression. The company’s RE104, a prodrug of synthetic psilocybin analog 4-OH-DiPT, has completed a Phase I trial, and is due to start the Phase II RECONNECT study this quarter...